secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sensei Biotherapeutics, Inc. (SNSE)
CIK:        0001829802
Form:       8-K
Filed at:   2022-12-08T23:59:59+00:00
Accession:  0001193125-22-300545
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 2.05, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sensei Biotherapeutics reduces workforce by 40%, closes Boston site, extends cash runway to H2 2025
--------------------------------------------------------------------------------

- Workforce reduction of ~40% to cut operating expenses; one-time charge of ~$1.0M expected in Q4 2022/Q1 2023.
- Boston research site closed; operations consolidated to Rockville, MD; cash runway extended into H2 2025.
- Robert Pierce terminated as Chief R&D Officer; moves to consulting role as Science Fellow effective Dec 7, 2022.
- Edward van der Horst promoted to Chief Scientific Officer effective Dec 7, 2022; oversees SNS-101 development.
- IND submission for lead antibody SNS-101 (anti-VISTA) anticipated by April 2023; discovery work on VSIG-4 and CD39 continues.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1829802/000119312522300545/0001193125-22-300545-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1829802/000119312522300545/d431901d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-300545

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer